Cassava Sciences: Two Undisclosed SEC Investigations Found
There's so much here, we had to write it up in a DI Report posted here for clients only.
(PDF with full report only visible if logged-in)
New - Confirmed, Undisclosed SEC investigative activity again found. In August, we took Cassava off the Watch List as we had new information that led us to believe there was no longer an ongoing, undisclosed SEC investigation here. To our surprise, we recently learned Cassava has been dealing with two undisclosed SEC investigations in the recent past; one remains ongoing. Both appear related to the company’s experimental Alzheimer’s drug, Simufilam.
The Cassava story is now long, complicated, and yet management still plays word games with investors about material and unnamed investigative exposures. Full details in today's report.
Important: The data reflected in this report are only current as of the dates indicated for each individual company. SEC investigative activity could theoretically begin or end after the date covered by the latest information in this report which would not be reflected here.
Similarly, public company disclosures made since the dates indicated herein could impact your analysis.
The SEC reminds us that its assertion of the law enforcement exemption should not be construed as an indication by the Commission or its staff that any violations of law have occurred with respect to any person, entity, or security.
Full disclosures and important additional information appear at the end of this report.
